JPMorgan Chase & Co. Sells 75,360 Shares of MediWound Ltd. (NASDAQ:MDWD)

JPMorgan Chase & Co. trimmed its holdings in MediWound Ltd. (NASDAQ:MDWD) by 95.7% in the 3rd quarter, HoldingsChannel reports. The firm owned 3,401 shares of the biopharmaceutical company’s stock after selling 75,360 shares during the quarter. JPMorgan Chase & Co.’s holdings in MediWound were worth $61,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. MetLife Investment Management LLC bought a new position in shares of MediWound during the 3rd quarter valued at approximately $89,000. Barclays PLC boosted its position in shares of MediWound by 311.3% during the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock valued at $202,000 after acquiring an additional 8,449 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of MediWound during the 3rd quarter valued at approximately $212,000. State Street Corp boosted its position in shares of MediWound by 219.6% during the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after acquiring an additional 45,529 shares during the last quarter. Finally, ARK Investment Management LLC bought a new position in shares of MediWound during the 3rd quarter valued at approximately $1,806,000. 46.83% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of MediWound in a research report on Friday, January 10th.

MediWound Stock Down 2.2 %

Shares of MDWD opened at $19.15 on Tuesday. The company has a market cap of $206.63 million, a PE ratio of -6.60 and a beta of 0.81. The business has a fifty day moving average of $17.87 and a 200 day moving average of $17.75. MediWound Ltd. has a 52-week low of $11.04 and a 52-week high of $24.00.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the prior year, the company earned ($0.24) earnings per share. As a group, research analysts anticipate that MediWound Ltd. will post -2.66 earnings per share for the current fiscal year.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.